APTX Stock Overview
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
Aptinyx Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.35|
|52 Week High||US$3.76|
|52 Week Low||US$0.33|
|1 Month Change||-46.50%|
|3 Month Change||-40.70%|
|1 Year Change||-84.09%|
|3 Year Change||-88.76%|
|5 Year Change||n/a|
|Change since IPO||-98.26%|
Recent News & Updates
Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study
Aptinyx (NASDAQ:APTX) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in ~300 patients with fibromyalgia — a disorder that causes widespread musculoskeletal pain. The main goal was the change from baseline in average daily pain as reported on the 0-to-10 numeric rating scale (NRS) during week 12 of the study. The company said that both doses did not show statistically significant separation from placebo. Patients on NYX-2925 at both doses showed a trend toward clinically meaningful improvement in pain, and some secondary goals, versus placebo by week 4. However, by week 12, the placebo group improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful, Aptinyx said in an Aug. 12 press release. NYX-2925 was well tolerated in the study, and no concerning safety issues were seen, according to the company. Aptinyx added that detailed data from the study continue to be evaluated.
|APTX||US Biotechs||US Market|
Return vs Industry: APTX underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: APTX underperformed the US Market which returned -9% over the past year.
|APTX Average Weekly Movement||17.5%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: APTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: APTX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson’s disease cognitive impairment.
Aptinyx Inc. Fundamentals Summary
|APTX fundamental statistics|
Is APTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APTX income statement (TTM)|
|Cost of Revenue||US$55.44m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.16|
|Net Profit Margin||0.00%|
How did APTX perform over the long term?See historical performance and comparison